Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen and Sanofi-Aventis Extend Alliance to Include Oncology Biomarker ID, Validation

NEW YORK, Feb. 7 (GenomeWeb News) - Ciphergen today said it will discover, validate, and identify biomarkers for a pre-clinical oncology drug efficacy study for Sanofi-Aventis.

 

Under the terms of the agreement, which is an extension of an earlier deal between the two companies, Ciphergen will analyze samples at one of its Biomarker Discovery Center laboratories using its suite of proteomic products, including PatternTrack Process and the ProteinChip System.

 

Financial terms were not disclosed.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.